COST-EFFECTIVENESS OF ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL COMPLICATIONS IN PATIENTS WITH PROSTATE CANCER-Reference-Cited by-同舟云学术

COST-EFFECTIVENESS OF ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL COMPLICATIONS IN PATIENTS WITH PROSTATE CANCER

Published:2004-04 Issue:4 Volume:171 Page:1537-1542
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

REED SHELBY D.¹,RADEVA JASMINA I.¹,GLENDENNING G. ALASTAIR¹,SAAD FRED¹,SCHULMAN KEVIN A.¹

Affiliation:

1. From the Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center (SDR, KAS, JIR), Durham, North Carolina, Novartis Pharmaceuticals Corp. (AG), East Hanover, New Jersey, and Centre Hospitalier de l’Université de Montréal, Hôpital Notre-Dame (FS), Montréal, Québec, Canada

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference15 articles.

1. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma;Carlin;Cancer,2000

2. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline;Berruti;J Urol,2000

3. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial;Rosen;Cancer J,2001

4. Coleman, R.E., Rosen, L.S., Gordon, D., Major, P., Kaminski, M., Apffelstaedt, J. et-al.: Zoledronic acid (4mg) significantly reduces the relative risk of developing a skeletal-related event compared with pamidronate (90mg) in patients with breast cancer and bone metastasis. Presented at 25th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 11–14, 2002

5. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma;Saad;J Natl Cancer Inst,2002

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Construction and validation of web-based nomograms for detecting and prognosticating in prostate adenocarcinoma with bone metastasis;Scientific Reports;2022-11-03

2. Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer;Prostate Cancer and Prostatic Diseases;2022-07-07

3. Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer;JNCI: Journal of the National Cancer Institute;2021-10-01

4. Pharmacoeconomics;Pharmacoepidemiology;2019-10-18

5. Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review;PLOS ONE;2018-12-05